Home / Stock ratings / GHRS

Stock rating

GH Research PLC (GHRS) Stock Rating & Analysis

As of November 20, 2026, MELANY rates GH Research PLC 53 out of 100 (Very Promising). Its highest factor score is earnings track record at 94, and its lowest are business quality and price momentum at 28.

MELANY ratingRated 2026-11-20

GHRS · composite score

53/100
Very Promising
Nov 20
Rating date
Live price in the app →
Quality28
Momentum28
Risk-adjusted45
Source basis SEC filings and live market dataDated snapshot

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company developing a treatment for depression, initially focused on proprietary mebufotenin therapies for patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, an inhalable mebufotenin candidate, and GH002, an intravenous mebufotenin candidate, and it operates in a single Research and Development segment.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why GHRS scores 53/100

GHRS's 8 factor scores run from 28 to 94, and 3 of them sit above its composite of 53. Here is how GHRS breaks down.

Valuation55/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality28/100

Margins, returns on capital, and balance-sheet strength.

Price momentum28/100

Direction and relative strength of the recent share-price trend.

Earnings track record94/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 3 of last 4 quarters
  • Avg EPS beat +19%
Analyst sentiment78/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 144% upside
Catalyst setup40/100

Near-term events that could move the stock.

Risk-adjusted profile45/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

Key risks for GHRS

  • Negative free cash flow, company consuming cash, not generating it
  • Weak price momentum, trend not yet confirmed, may need more time to set up
  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt
  • No positive trailing earnings, valuation cannot be anchored to current P/E

Sector and theme context

GH Research PLC sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds GHRS's momentum and catalyst factors above.

GHRS trade plan (Pro)

MELANY has a full position plan for GH Research PLC: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates GHRS

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. GH Research PLC's 53/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about GHRS

Is GH Research PLC (GHRS) a buy?

As of 2026-11-20, MELANY rated GH Research PLC Very Promising with a composite score of 53/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

Should I buy GH Research PLC stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates GH Research PLC (GHRS) Very Promising with a composite of 53/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the GHRS stock price forecast?

MELANY does not publish price targets or forecasts for GHRS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 53/100 across eight factors for GH Research PLC, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for GHRS as of 2026-11-20: its analyst sentiment factor is 78/100 (Analyst targets 144% upside), and its price momentum factor is 28/100.

Is GHRS stock overvalued or undervalued?

MELANY's valuation factor currently reads 55/100 for GH Research PLC, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives GHRS's read.

What price should I buy GHRS at?

Rather than chasing the current price, MELANY computes a smart entry zone for GHRS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying GHRS stock?

The top risks MELANY currently flags for GH Research PLC: Negative free cash flow, company consuming cash, not generating it; Weak price momentum, trend not yet confirmed, may need more time to set up; Performance partly driven by Healthcare sector, rotation away from this theme would hurt; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is GH Research PLC a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 28/100 for GH Research PLC, and earnings track record, at 94/100. The 53/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will GHRS stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 28/100 for GHRS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this GHRS rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores GHRS as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, GHRS included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.